BR112017009476A2 - unidade polimérica de dispositivo para fármaco, métodos para preparação de uma unidade polimérica de dispositivo para fármaco e para tratamento e/ou prevenção da endometriose, uso de uma unidade polimérica de dispositivo para fármaco, kit, metabolitos de quinagolida, e, uso de metabolitos de quinagolida. - Google Patents

unidade polimérica de dispositivo para fármaco, métodos para preparação de uma unidade polimérica de dispositivo para fármaco e para tratamento e/ou prevenção da endometriose, uso de uma unidade polimérica de dispositivo para fármaco, kit, metabolitos de quinagolida, e, uso de metabolitos de quinagolida.

Info

Publication number
BR112017009476A2
BR112017009476A2 BR112017009476A BR112017009476A BR112017009476A2 BR 112017009476 A2 BR112017009476 A2 BR 112017009476A2 BR 112017009476 A BR112017009476 A BR 112017009476A BR 112017009476 A BR112017009476 A BR 112017009476A BR 112017009476 A2 BR112017009476 A2 BR 112017009476A2
Authority
BR
Brazil
Prior art keywords
drug device
polymeric unit
quinagolide
device polymeric
drug
Prior art date
Application number
BR112017009476A
Other languages
English (en)
Other versions
BR112017009476B1 (pt
Inventor
Ross Alistair
Young Claire
Carr Denis
Halliday Janet
Qadir Mohammad
Mcdonald Paul
Cochrane Robert
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017009476(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR112017009476A2 publication Critical patent/BR112017009476A2/pt
Publication of BR112017009476B1 publication Critical patent/BR112017009476B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/001Combinations of extrusion moulding with other shaping operations
    • B29C48/0021Combinations of extrusion moulding with other shaping operations combined with joining, lining or laminating
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035Medical or pharmaceutical agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29LINDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00Other particular articles
    • B29L2031/753Medical equipment; Accessories therefor
    • B29L2031/754Pessaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)

Abstract

a presente invenção baseia-se na identificação de um grupo de copolímeros em blocos de poliuretano que são particularmente adequados para uso em unidades poliméricas farmacêuticas de dispositivo para fármaco e que oferecem um controle melhorado da liberação de fármaco. em particular, é provida uma unidade polimérica de dispositivo para fármaco compreendendo um copolímero em bloco de poliuretano que pode ser obtido por reação conjunta de um poli(óxido de alquileno); um composto difuncional; um isocianato difuncional; e opcionalmente um copolímero em bloco compreendendo blocos de poli(óxido de alquileno); e quinagolida como um agente farmaceuticamente ativo. as unidades de dispositivo para fármaco podem encontrar aplicação no tratamento e/ou prevenção da endometriose.
BR112017009476-2A 2014-11-07 2015-11-05 Unidade polimérica de dispositivo para fármaco, método para preparação de uma unidade polimérica de dispositivo para fármaco, uso de uma unidade polimérica de dispositivo para fármaco, e, kit BR112017009476B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192372.2A EP3017809A1 (en) 2014-11-07 2014-11-07 Drug-device unit containing quinagolide
EP14192372.2 2014-11-07
PCT/EP2015/075849 WO2016071466A1 (en) 2014-11-07 2015-11-05 Drug-device unit containing quinagolide

Publications (2)

Publication Number Publication Date
BR112017009476A2 true BR112017009476A2 (pt) 2018-01-02
BR112017009476B1 BR112017009476B1 (pt) 2023-08-01

Family

ID=

Also Published As

Publication number Publication date
JO3561B1 (ar) 2020-07-05
PH12017550005A1 (en) 2017-10-18
MA40897A (fr) 2017-09-13
AU2015341734B2 (en) 2020-08-20
TN2017000175A1 (en) 2018-10-19
RS62018B1 (sr) 2021-07-30
TW201625245A (zh) 2016-07-16
EA201991882A2 (ru) 2020-01-31
CN106999422A (zh) 2017-08-01
TWI685339B (zh) 2020-02-21
UA122329C2 (uk) 2020-10-26
EA033806B9 (ru) 2019-12-19
EP3017809A1 (en) 2016-05-11
US20220040094A1 (en) 2022-02-10
MD3215118T2 (ro) 2021-08-31
JP2021155444A (ja) 2021-10-07
CN116212032A (zh) 2023-06-06
LT3215118T (lt) 2021-06-10
EA201790898A1 (ru) 2017-11-30
WO2016071466A1 (en) 2016-05-12
AR102571A1 (es) 2017-03-08
PT3215118T (pt) 2021-05-31
DK3215118T3 (da) 2021-06-21
EP3215118A1 (en) 2017-09-13
CL2017001119A1 (es) 2018-01-05
JP2017533272A (ja) 2017-11-09
ES2877973T3 (es) 2021-11-17
KR102612852B1 (ko) 2023-12-11
SI3215118T1 (sl) 2021-08-31
KR20170080671A (ko) 2017-07-10
CO2017005578A2 (es) 2017-08-31
IL252088B (en) 2022-04-01
AU2020270480A1 (en) 2020-12-17
EA201790898A8 (ru) 2018-01-31
MY193638A (en) 2022-10-21
SG11201703596SA (en) 2017-06-29
EP3892261A1 (en) 2021-10-13
EP3215118B1 (en) 2021-03-17
PL3215118T3 (pl) 2021-07-26
EA033806B1 (ru) 2019-11-27
MX2017005828A (es) 2017-11-13
AU2015341734A1 (en) 2017-06-01
MA40897B1 (fr) 2021-04-30
HUE054951T2 (hu) 2021-10-28
IL252088A0 (en) 2017-07-31
US20180008535A1 (en) 2018-01-11
CA2966473A1 (en) 2016-05-12
HRP20210961T1 (hr) 2021-09-17
JP6907120B2 (ja) 2021-07-21
SA517381471B1 (ar) 2022-03-06
MA56414A (fr) 2022-05-04
AU2015341734C1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
BR112019005615A8 (pt) Filme para um dispositivo médico ou embalagem, filme de curativo de ferida, e método de fabricação de um dispositivo médico
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
CA2956871C (en) Compounds active towards bromodomains
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
CO2017005578A2 (es) Unidad de dispositivo de droga que contiene quinagolida
BR112018072664A2 (pt) composições e métodos para tratamento de inflamação e infecção do olho
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
BR112018071394A2 (pt) polímero de enxerto, métodos para a preparação de um polímero de enxerto, para a preparação de um sistema de dispensação e para prevenir, tratar ou melhorar um distúrbio médico, composição, preenchedor de tecido macio, uso de um polímero de enxerto, e, kit.
BR112016025244A2 (pt) uso de ácido 1,3-propanodissulfônico ou sais farmaceuticamente aceitáveis dos mesmos para o tratamento de sarcoidose.
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
BR112012028267A2 (pt) formulações de acetonida de triancinolona para tratamento dermatite e psoríase
BR112018070526A2 (pt) tratamento do carcinoma de células renais com lenvatinibe e everolimo
CL2022000226A1 (es) Método de fabricación de microestructuras
TH1701002526A (th) หน่วยอุปกรณ์ส่งยาที่มีควินาโกไลด์
IN2013MU03612A (pt)
IN2013MU03668A (pt)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/11/2015, OBSERVADAS AS CONDICOES LEGAIS